KEGG   DRUG: Crisantaspase
Entry
D10517                      Drug                                   
Name
Crisantaspase (JAN/INN);
Enrylaze (TN);
Erwinase (TN)
Formula
C1546H2510N432O476S9
Exact mass
35032.2968
Mol weight
35053.6654
Sequence
ADKLPNIVIL ATGGTIAGSA ATGTQTTGYK AGALGVDTLI NAVPEVKKLA NVKGEQFSNM
ASENMTGDVV LKLSQRVNEL LARDDVDGVV ITHGTDTVEE SAYFLHLTVK SDKPVVFVAA
MRPATAISAD GPMNLLEAVR VAGDKQSRGR GVMVVLNDRI GSARYITKTN ASTLDTFKAN
EEGYLGVIIG NRIYYQNRID KLHTTRSVFD VRGLTSLPKV DILYGYQDDP EYLYDAAIQH
GVKGIVYAGM GAGSVSVRGI AGMRKAMEKG VVVIRSTRTG NGIVPPDEEL PGLVSDSLNP
AHARILLMLA LTRTSDPKVI QEYFHTY
  Type
Peptide
Source
Erwinia chrysanthemi [TAX:556]
Remark
Therapeutic category: 4291
ATC code: L01XX02
Product: D10517<JP>
Efficacy
Antineoplastic
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01X OTHER ANTINEOPLASTIC AGENTS
    L01XX Other antineoplastic agents
     L01XX02 Asparaginase
      D10517  Crisantaspase (JAN/INN) <JP>
Therapeutic category of drugs in Japan [BR:br08301]
 4  Agents affecting cellular function
  42  Antineoplastics
   429  Miscellaneous
    4291  Other Antitumors
     D10517  Crisantaspase (JAN/INN)
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D10517
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D10517
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D10517
Other DBs
PubChem: 172232610
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system